Gan Li Pharmaceutical: Injection GLR1059 receives approval notice for drug clinical trial.

Ganli Pharmaceutical announced that it has recently received a notice from the State Food and Drug Administration regarding the approval of clinical trials for the investigational drug GLR1059 for injection. The acceptance number is CXSL2600182, and the notice number is 2026LP01219. GLR1059 for injection is a targeted antibody-drug conjugate developed by Ganli Pharmaceutical, consisting of a specific humanized IgG1 monoclonal antibody, a cleavable linker, and the payload Elotuzumab targeting Nectin-4. Nectin-4 is significantly overexpressed in various malignant tumor tissues such as breast cancer, lung cancer, urothelial carcinoma, colorectal cancer, pancreatic cancer, and ovarian cancer.